221 CRESCENT STREET, WALTHAM, MA
Financial Results, Press Release
Investor Presentation
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics Enters Underwriting Agreement for $275 Million Offering
Spyre Therapeutics Reports Preliminary Cash Position of $486.2 Million
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Shareholder votes
FY 2024
Q3
Q2
Q1
Amended Quarterly Report
Amended Annual Report
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence